Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI113266

In vivo metabolism of proapolipoprotein A-I in Tangier disease.

D Bojanovski, R E Gregg, L A Zech, M S Meng, C Bishop, R Ronan, and H B Brewer Jr

Molecular Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892.

Find articles by Bojanovski, D. in: PubMed | Google Scholar

Molecular Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892.

Find articles by Gregg, R. in: PubMed | Google Scholar

Molecular Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892.

Find articles by Zech, L. in: PubMed | Google Scholar

Molecular Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892.

Find articles by Meng, M. in: PubMed | Google Scholar

Molecular Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892.

Find articles by Bishop, C. in: PubMed | Google Scholar

Molecular Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892.

Find articles by Ronan, R. in: PubMed | Google Scholar

Molecular Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892.

Find articles by Brewer, H. in: PubMed | Google Scholar

Published December 1, 1987 - More info

Published in Volume 80, Issue 6 on December 1, 1987
J Clin Invest. 1987;80(6):1742–1747. https://doi.org/10.1172/JCI113266.
© 1987 The American Society for Clinical Investigation
Published December 1, 1987 - Version history
View PDF
Abstract

Tangier disease is a rare familial disorder characterized by extremely low levels of apolipoprotein A-I (apoA-I) and high density lipoproteins (HDL). In normal subjects, proapoA-I is secreted into plasma and converted to mature apoA-I by the cleavage of the amino-terminal six amino acids with the major isoprotein in plasma being mature apoA-I. In contrast, in Tangier disease there is a marked relative increase of proapoA-I as compared with mature apoA-I. ProapoA-I and mature apoA-I were isolated from normal and Tangier disease subjects, radio-labeled, and autologous apoA-I isoproteins injected into normal and Tangier subjects. The in vivo catabolism and conversion of proapoA-I and mature apoA-I in normal and Tangier disease subjects were quantitated. A comparison of the rate of catabolism of apoA-I isoproteins from plasma revealed a significantly faster rate of catabolism of both isoproteins of apoA-I in Tangier subjects when compared with normal subjects. The fractional conversion rate of proapoA-I to mature apoA-I was 3.9 d-1 in normal subjects and 3.6 d-1 in Tangier subjects. The results indicate that (a) apoA-I enters plasma as the pro isoprotein in both normal and Tangier subjects, (b) Tangier disease subjects have a normal fractional rate of conversion of proapoA-I to mature apoA-I, (c) proapoA-I is catabolized at the same rate as mature apoA-I in Tangier subjects, and (d) Tangier subjects catabolize both pro and mature apoA-I at a much greater rate than do normal subjects. Therefore, the relative increase in proapoA-I in Tangier disease is due to a marked decrease in mature apoA-I resulting from rapid catabolism of both pro- and mature apoA-I and not to defective conversion of proapoA-I to mature apoA-I.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1742
page 1742
icon of scanned page 1743
page 1743
icon of scanned page 1744
page 1744
icon of scanned page 1745
page 1745
icon of scanned page 1746
page 1746
icon of scanned page 1747
page 1747
Version history
  • Version 1 (December 1, 1987): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts